▼ 0.05%
prev close
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Congressional Trades
10
All tracked trades
Members Trading
7
Unique members
Net Activity
+2
6 buys · 4 sells
Members Who Traded This Stock
10 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2025-09-23 | GILDGilead Sciences Inc | Sell | $1,001 - $15,000 | 236d ago | — | |
| 2025-05-05 | GILDGilead Sciences Inc | Buy | $1,001 - $15,000 | 393d ago | — | |
| 2025-04-16 | GILDGilead Sciences Inc | Sell | $1,001 - $15,000 | 385d ago | — | |
| 2025-03-10 | GILDGilead Sciences Inc | Buy | $1,001 - $15,000 | 418d ago | — | |
| 2025-03-07 | GILDGilead Sciences Inc | Buy | $1,001 - $15,000 | 419d ago | — | |
| 2024-10-29 | GILDGilead Sciences Inc | Buy | $1,001 - $15,000 | 264d ago | — | |
| 2023-09-26 | GILDGilead Sciences Inc | Buy | $1,001 - $15,000 | 937d ago | — | |
| 2023-07-12 | GILDGilead Sciences Inc | Sell | $15,001 - $50,000 | 1025d ago | — | |
| 2023-03-06 | GILDGilead Sciences Inc | Buy | $15,001 - $50,000 | 1143d ago | — | |
| 2021-11-10 | GILDGilead Sciences Inc | Sell | $15,001 - $50,000 | 1370d ago | — |
2025-09-23
Valerie Hoyle
GILD
Amount
$1,001 - $15,000
Filed
236d ago
2025-05-05
Marjorie Taylor Greene
GILD
Amount
$1,001 - $15,000
Filed
393d ago
2025-04-16
John Boozman
GILD
Amount
$1,001 - $15,000
Filed
385d ago
2025-03-10
Carol Devine Miller
GILD
Amount
$1,001 - $15,000
Filed
418d ago
2025-03-07
Josh Gottheimer
GILD
Amount
$1,001 - $15,000
Filed
419d ago
2024-10-29
Valerie Hoyle
GILD
Amount
$1,001 - $15,000
Filed
264d ago
2023-09-26
Greg Stanton
GILD
Amount
$1,001 - $15,000
Filed
937d ago
2023-07-12
Daniel Goldman
GILD
Amount
$15,001 - $50,000
Filed
1025d ago
2023-03-06
Daniel Goldman
GILD
Amount
$15,001 - $50,000
Filed
1143d ago
2021-11-10
Carol Devine Miller
GILD
Amount
$15,001 - $50,000
Filed
1370d ago
Recent News
Powered by Polygon.io
Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More
Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases
Nurix Therapeutics to Participate in Upcoming Investor Conferences
Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference
Trade Timeline
Congressional activity, newest first
Valerie Hoyle
2025-09-23 · Sale
$1,001 - $15,000
Marjorie Taylor Greene
2025-05-05 · Purchase
$1,001 - $15,000
John Boozman
2025-04-16 · Sale
$1,001 - $15,000
Carol Devine Miller
2025-03-10 · Purchase
$1,001 - $15,000
Josh Gottheimer
2025-03-07 · Purchase
$1,001 - $15,000
Valerie Hoyle
2024-10-29 · Purchase
$1,001 - $15,000
Greg Stanton
2023-09-26 · Purchase
$1,001 - $15,000
Daniel Goldman
2023-07-12 · Sale
$15,001 - $50,000
Daniel Goldman
2023-03-06 · Purchase
$15,001 - $50,000
Carol Devine Miller
2021-11-10 · Sale
$15,001 - $50,000